NASDAQ:AYTUAytu Bioscience Stock Price, Forecast & News

Aytu Bioscience's stock was trading at $1.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AYTU stock has increased by 12.2% and is now trading at $1.5150. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu Bioscience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aytu Bioscience.

Aytu Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, September 24th 2020. View our earnings forecast for Aytu Bioscience.

Aytu Bioscience Inc (NASDAQ:AYTU) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. The company had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7 million. Aytu Bioscience had a negative return on equity of 107.69% and a negative net margin of 172.62%. View Aytu Bioscience's earnings history.

Aytu Bioscience shares reverse split before market open on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.

1 Wall Street analysts have issued 1 year price objectives for Aytu Bioscience's stock. Their forecasts range from $4.75 to $5.00. On average, they anticipate Aytu Bioscience's stock price to reach $4.88 in the next twelve months. This suggests a possible upside of 221.8% from the stock's current price. View analysts' price targets for Aytu Bioscience.

Headlines about AYTU stock have been trending negative on Tuesday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aytu Bioscience earned a news impact score of -2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAytu Bioscience.

Some companies that are related to Aytu Bioscience include Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), Homology Medicines (FIXX), Nabriva Therapeutics (NBRV), Ardelyx (ARDX), Akero Therapeutics (AKRO), Assembly Biosciences (ASMB), G1 Therapeutics (GTHX), Morphic (MORF), Sinovac Biotech (SVA), Provention Bio (PRVB), Stemline Therapeutics (STML), DiaMedica Therapeutics (DMCAF) and Vanda Pharmaceuticals (VNDA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu Bioscience investors own include Vaxart (VXRT), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Heat Biologics (HTBX) and Crispr Therapeutics (CRSP).

Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."

Aytu Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Searle & CO. (0.17%), Soleus Capital Management L.P. (0.15%), ETRADE Capital Management LLC (0.08%), BlackRock Inc. (0.03%), HCR Wealth Advisors (0.02%) and HighTower Advisors LLC (0.02%). Company insiders that own Aytu Bioscience stock include Armistice Capital Master Fund, David A Green and Joshua R Disbrow. View institutional ownership trends for Aytu Bioscience.

AYTU stock was sold by a variety of institutional investors in the last quarter, including Searle & CO.. View insider buying and selling activity for Aytu Bioscience.

AYTU stock was bought by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., ETRADE Capital Management LLC, HCR Wealth Advisors, HighTower Advisors LLC, and BlackRock Inc.. Company insiders that have bought Aytu Bioscience stock in the last two years include Armistice Capital Master Fund, and Joshua R Disbrow. View insider buying and selling activity for Aytu Bioscience.

Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AYTU stock can currently be purchased for approximately $1.52.

Aytu Bioscience has a market capitalization of $182.19 million and generates $7.32 million in revenue each year. The company earns $-27,130,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. Aytu Bioscience employs 52 workers across the globe.

The official website for Aytu Bioscience is aytubio.com.

Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]